A paradigm shift in the medical treatment of acromegaly: from a ‘trial and error’ to a personalized therapeutic decision-making process-Reference-Cited by-同舟云学术

A paradigm shift in the medical treatment of acromegaly: from a ‘trial and error’ to a personalized therapeutic decision-making process

Published:2015-05-13 Issue:1 Volume:83 Page:1-2
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clin Endocrinol

Author:

Gadelha Mônica R.¹

Affiliation:

1. Neuroendocrinology Research Center/Endocrine Section; Medical School and Hospital Universitário Clementino Fraga Filho; Universidade Federal do Rio de Janeiro; Rio de Janeiro Brazil

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Reference15 articles.

1. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly;Holdaway;European Journal of Endocrinology,2008

2. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic;Mercado;The Journal of Clinical Endocrinology and Metabolism,2014

3. Systemic complications of acromegaly: epidemiology, pathogenesis, and management;Colao;Endocrine Reviews,2004

4. Acromegaly: an endocrine society clinical practice guideline;Katznelson;The Journal of Clinical Endocrinology and Metabolism,2014

5. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’;Nomikos;European Journal of Endocrinology,2005

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative therapeutics in acromegaly;Best Practice & Research Clinical Endocrinology & Metabolism;2022-12

2. Data mining analyses for precision medicine in acromegaly: a proof of concept;Scientific Reports;2022-05-28

3. Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length;Pituitary;2021-11-10

4. The Future of Somatostatin Receptor Ligands in Acromegaly;The Journal of Clinical Endocrinology & Metabolism;2021-10-07

5. gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly;Cancers;2021-09-28